|
The study Birgitta mentions, of Revlimid and Vidaza in combination, was written up in 2010 so the data is from 2010 and earlier. It was a Phase I trial, meaning that it was intended primarily as a test of safety, not efficacy. There were only 18 patients, but the response rate was good, seeming to indicate that the drugs complemented each other and didn't raise toxicity, and therefore that the combination is promising and worth studying in larger patient populations.
|